LA
INFI

Lee Ainslie’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Lee Ainslie’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-17,200
Closed -$240K – 136
2015
Q1 		$240K Buy
+17,200
New +$263K ﹤0.01% 116

Other funds holding INFI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Lee Ainslie's INFI Position: Q2 2015 in Review

Lee Ainslie sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2015, closing a stake of 17,200 shares — an estimated $240K sold.

Lee Ainslie first reported a position in INFI in Q1 2015 and held it in 1 quarter. The position peaked at $240K in Q1 2015. 137 funds tracked by Wall St. Rank hold INFI as of Q2 2015.

  • Lee Ainslie reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Lee Ainslie sold 17,200 Infinity Pharmaceuticals, Inc. shares in Q2 2015, an estimated $240K.
  • Lee Ainslie first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Lee Ainslie's Infinity Pharmaceuticals, Inc. position peaked at $240K in Q1 2015.
  • 137 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2015.

Based on Maverick Capital's 13F filing for Q2 2015, filed 14 Aug 2015.